✦ LIBER ✦

Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia

✍ Scribed by Masaomi Iyo; Yukihiko Shirayama; Hiroyuki Watanabe; Mihisa Fujisaki; Ryosuke Miyatake; Goro Fukami; Akihiro Shiina; Michiko Nakazato; Tetsuya Shiraishi; Tsuyoshi Ookami; Kenji Hashimoto

Book ID: 116841264
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 101 KB
Volume: 32
Category: Article
ISSN: 0278-5846
DOI: 10.1016/j.pnpbp.2008.01.005

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Fluvoxamine improved cognitive impairmen

Fluvoxamine improved cognitive impairments in a patient with schizophrenia

✍ Tomihisa Niitsu; Yukihiko Shirayama; Mihisa Fujisaki; Kenji Hashimoto; Masaomi I 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 118 KB

A reversible model of the cognitive impa

A reversible model of the cognitive impairment associated with schizophrenia in monkeys: Potential therapeutic effects of two nicotinic acetylcholine receptor agonists

✍ Jerry J. Buccafusco; Alvin V. Terry Jr. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 651 KB

Binding of a tritiated inverse agonist t

Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia

✍ Kimberly J. Jenko; Jussi Hirvonen; Ioline D. Henter; Kacey B. Anderson; Sami S. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 217 KB

Treatment of cognitive dysfunction in ch

Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT1A receptor agonist

✍ Danijela Piškulić; James S. Olver; Paul Maruff; Trevor R. Norman 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB

## Abstract ## Objectives To assess effects of a semi‐acute administration of buspirone in comparison to a placebo on cognitive function and negative symptoms in patients with schizophrenia and schizoaffective disorder. ## Methods In a 6‐week, double‐blind, placebo‐controlled, independent groups

P.1.a.013 T102c polymorphism of serotoni

P.1.a.013 T102c polymorphism of serotonin-2a receptor gene in schizophrenia: association with cognitive impairment and soft neurological signs

✍ B.C. Poyraz; A. Ozcetin; C. Aksoy Poyraz; E. Bozhuyuk; N. Bolat; I. Balcioglu; A 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 78 KB

AVE1625, a cannabinoid CB1 receptor anta

AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents

✍ Mark D. Black; Rachel J. Stevens; Nancy Rogacki; Robert E. Featherstone; Yaw Sen 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 420 KB